Short answer
Benitec Biopharma Inc. (BNTC) filed its Q1 2026 10-Q quarterly report on May 14, 2026 for the quarter ended Mar 31, 2026. Quarterly revenue was $0 with net income of −$12M.
Q1 2026 key financials · XBRL
- Revenue
- $0
- Net income
- −$12M
- +28.6% YoY · −0.8% QoQ
- EPS (diluted)
- −$0.24
- −60.0% YoY · +7.7% QoQ
Source: XBRL data from the Benitec Biopharma Inc. (BNTC) Q1 2026 10-Q on SEC EDGAR. USD.
Benitec Biopharma Inc. Q1 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Risk Factors
- No risk factors provided in the submitted excerpt
- No new or changed risks identifiable from Items 2–6
- Regulatory disclosure limited to Sarbanes-Oxley certification exhibits
- No liquidity, debt, currency, concentration, operational, or competitive risks disclosed
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Benitec Biopharma Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.